Study Objective: Explore how the introduction of 4-factor prothrombin complex concentrates (4F-PCC) protocols for reversing anticoagulation and the treatment of critical bleeding influenced blood product utilization.
Design: A retrospective analysis of the utilization rate of plasma and 4F-PCC from September 2012 through December 2018.
Setting: Blood bank and pharmacy records of a single large tertiary care medical center.
Background: The acute respiratory illness designated coronavirus disease 2019 (COVID-19) was first reported in Wuhan, China, in December 2019 and caused a worldwide pandemic. Concerns arose about the impact of the COVID-19 pandemic on blood donations and potential significant blood transfusion needs in severely ill COVID-19 patients. Data on blood usage in hospitalized COVID-19 patients are scarce.
View Article and Find Full Text PDF